RSV Vaccine Market Growth

Rising Prevalence of Infectious Diseases to Support the RSV Vaccine Market Growth | Roots Analysis

According to a recently published report by Roots Analysis, the rising prevalence of respiratory syncytial virus (RSV) infections along with the growing adoption of preventive therapies such as RSV vaccines is driving the growth of RSV vaccine market

RSV Vaccine Industry Overview

The RSV vaccine market size is anticipated to be USD 731 million by 2040, as more approved vaccines reach the market and owing to the aging population.

RSV vaccines are preventive immunotherapies developed against respiratory syncytial virus (RSV), a virus known to cause lower respiratory tract infections in young children and older adults. These vaccines contain attenuated or inactive virus forms that triggers a strong immune response within the body. Further, these vaccines produce neutralizing antibodies that are believed to confer immunity for longer period of time in order to prepare the immune system to combat future RSV infections.

As a result, RSV vaccines have demonstrated significant reduction in disease recurrence as well as an increase in life expectancy of patients suffering with RSV infections. Owing to such positive outcomes of these vaccines, recent advancements in RSV vaccine technology and development platforms, such as nanoparticle and mRNA-based technologies have been made to provide more effective protection against RSV.

As research continues, more vaccines are expected to reach the market and significantly reduce the global RSV-related morbidity and mortality.

Browse 85+ figures and 70+ market data tables spread across 195+ slides and detailed Table of Content on “RSV Vaccine Market, till 2040 by Type of Vaccine, Route of Administration, Target Patient Population, Distribution Channel, Key Geographical Regions and Leading Players” here:

Market Drivers

A range of factors are compelling the global RSV vaccine market growth. One of the key factors driving the future of RSV vaccine market is the growing burden of RSV diseases. According to the American Heart Association, around 65 million people are reported to have RSV infection each year, globally. This underlines the growing awareness about RSV diseases and its potential impact on vulnerable populations, which acts as a crucial driver for the development of innovative RSV vaccines. Further, the emerging technologies such as vector-based and mRNA-based platforms for vaccine development acts as a crucial factor in strengthening the RSV vaccine industry.

Market Restraints

There are certain restraints that can hinder the growth of this industry. One of the primary restraints is the high cost of vaccine development and production, ultimately resulting in fewer candidates entering the clinical pipeline. Additionally, the high recurrence rate and variable vaccine efficiency across different target population also pose significant barriers for the adoption of RSV vaccines. Moreover, inadequate preclinical data on RSV vaccines has increased the risk of failure, creating uncertainties about their safety and efficacy, making the RSV vaccine market less attractive for both private and public investors.

Growth Factors

Despite the challenges, multiple factors continue to drive the RSV vaccine market growth. One notable factor is the increasing geriatric and pediatric population, as they are more susceptible to RSV infections. Further, the active involvement of global health organizations and institutional boards such as WHO in prioritizing the expedited pathways for vaccine development are increasing in order to reform the policies for RSV vaccines.

RSV Vaccine Market Segments

Based on the type of vaccine, the market is segmented into Subunit / Viral-like-Particle (VLP) Vaccines, Live Attenuated Vaccines and mRNA Vaccines

• Subunit / Viral-like-Particle (VLP) vaccines led the RSV vaccine market, capturing the largest revenue share (98%) in the current year.
• Live Attenuated vaccines are anticipated to grow at a CAGR of 0.2%, during the forecast period.

Based on the route of administration, the market is segmented into Intramuscular and Other Routes

• The intramuscular route led the RSV vaccine market, capturing the entire revenue share of 100% in the current year.
• The other routes segment, such as intranasal, intradermal and oral are anticipated to emerge during the forecast period.

Based on the target patient population, the market is segmented into Elderly Individuals, Infants / Children and Pregnant Individuals

• The RSV vaccines for elderly individuals led the RSV vaccine market, capturing the largest revenue share of around 95% in the current year.
• The RSV vaccines for infants / children are anticipated to enter the RSV vaccines domain, during the forecast period.

Based on the distribution channel, the market is segmented into Pharmacies and Drug Stores, Government / Institutional Suppliers and Others

• The Pharmacies and Drug Stores led the RSV vaccine market, capturing the largest revenue share of 80% in the current year.
• The Others segment is anticipated to be the fastest growing segment in this industry, with an annualized rate of 3.9% during the forecast period.

Based on geography, the market is segmented into North America and Europe

• North America dominated the RSV vaccine market and accounted for the largest revenue share of around 85% in the current year.
• In Europe, the RSV vaccine market is anticipated to capture 15% of the overall market share, during the forecast period.

Key Companies Profiled

The RSV vaccine market report also includes detailed profiles of key developers (listed below) that offer RSV vaccines:

• Beijing Advaccine Biotechnology
• GlaxoSmithKline
• Icosavax (A company of AstraZeneca)
• Moderna
• Pfizer
• Sanofi

You Can Download Free Sample PDF Copy Of This Report At: https://www.rootsanalysis.com/reports/rsv-vaccine-market/request-sample.html

About Roots Analysis

Roots Analysis is a global leader in market research, competitive intelligence and consulting services. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary

Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com